Melanoma-associated antigen A family (MAGE-A)

The Melanoma-associated antigen A (MAGE-A) family, specifically MAGE-A1 and MAGE-A3, are prominent members of the Type I Cancer-Testis Antigen (CTA) group. These proteins are typically expressed only in male germ cells and the placenta, which lack MHC expression, making them effectively tumor-specific when expressed in various malignancies such as melanoma and lung cancer (UniProt P43355, P43357). MAGE-A proteins function as scaffolds for E3 ubiquitin ligases, influencing cell cycle progression and apoptosis to promote tumor survival. Because they are intracellular, they are targeted via T-cell receptors (TCRs) that recognize MAGE-derived peptides presented on the cell surface by HLA molecules (PMID: 23943307). Therapeutic approaches include TCR-engineered T-cells (TCR-T) and bispecific T-cell engagers (ImmTACs) designed to exploit this peptide-MHC recognition. However, high sequence homology between MAGE-A members poses a risk of cross-reactivity, which has historically led to severe adverse events, such as neurotoxicity when TCRs inadvertently targeted MAGE-A12 in the central nervous system (PMID: 23943307). Current drug development focuses on enhancing the specificity of these TCR-based therapies to minimize off-target effects while maximizing the broad anti-tumor potential of targeting multiple MAGE-A family members (ClinicalTrials.gov NCT03686124).

Other names

MAGE-A1MAGE-A3Melanoma-associated antigen 1Melanoma-associated antigen 3Cancer-testis antigenMAGE-A familyMAGEA1MAGEA3Melanoma antigen family A

T-cell receptor (TCR) mediated recognition of specific MAGE-A peptides presented by Major Histocompatibility Complex (MHC) molecules, leading to T-cell activation and targeted lysis of tumor cells.